NASDAQ: ONCO · Life Sciences · 6 alerts · CIK 1782107
Share price
$2.91Close, Nov 16
Market cap
$11.5M
Shares outstanding
3.95MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Onconetix, Inc. filings on SEC EDGAR ↗
Onconetix, Inc. held its 2026 Annual Meeting of Stockholders on November 10, 2026, where shareholders approved all five proposals. Key outcomes included the election of Josh Epstein as a Class II director, the ratification of MaloneBailey, LLP as auditors, and the grant of discretionary authority to the Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-15.
Onconetix, Inc. implemented a one-for-ten (1:10) reverse stock split of its common stock effective November 6, 2026. The split reduced the number of outstanding shares from approximately 6.7 million to 670,000 to satisfy Nasdaq listing requirements. Trading commenced on a split-adjusted basis under the existing symbol 'ONCO' with a new CUSIP number.
Onconetix entered into a first amendment to its existing share exchange agreement with Realbotix Corp. to acquire Realbotix, LLC. The amendment modifies the ownership structure such that the seller will own 95% of the buyer if net cash is less than $12.5 million and extends the deal's outside closing date to March 31, 2027.
Onconetix, Inc. announced a 1-for-10 reverse stock split of its common stock, effective November 6, 2026. This follows a previous 1-for-10 split in May 2026, resulting in a cumulative 1-for-100 consolidation to reduce outstanding shares from approximately 5.9 million to 589,000. The action is intended to adjust the per-share trading price on the Nasdaq Capital Market.
Onconetix Equity Investment of $500K in Realbotix, LLC
Onconetix, Inc. made an additional $500,000 cash advance to Realbotix, LLC under an existing Grid Promissory Note. This brings the total aggregate principal amount outstanding under the note to $3.0 million out of a total $5.0 million facility.
Onconetix provided a $5.0 million strategic bridge financing facility to Realbotix, LLC, the target of its previously announced pending acquisition. The facility is non-interest bearing and will be automatically cancelled and discharged upon the closing of the all-stock merger. This update supports the working capital needs of Realbotix as the parties work toward completing the transaction.